Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings Strategy Biosimilars

Coherus Looks To Galvanize Pegfilgrastim Biosimilar With New Formats

California-Based Firm Updates On Planned Novel Autoinjector Presentation

  • Analysis

Executive Summary

Coherus BioSciences spoke at length about its two marketed biosimilars, referencing Neulasta and Lucentis, during the company’s first-quarter earnings call.

You may also be interested in...



Accord Sees Benefits From Unique Portfolio

With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.

Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023

At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).

Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval

Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings Strategy Biosimilars
Latest Headlines

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023

Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

See All
UsernamePublicRestriction

Register

GB152706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By